Skip to main contentSkip to navigationSkip to search

Viral Vectors

NorthX Biologics supports cell and gene therapy (CGT) projects from pre-clinical through to commercial manufacture.  We can produce Adeno-associated virus (AAV), Adenovirus (AV), Lenti-virus (LV) and retro virus (RV) for GMP and non GMP applications.

We pair this with our Process Development, Analytical Development and Plasmid DNA supply in order to give our clients a simple and fast approach to CGT applications.

NorthX offers complete viral vector

production solutions

Plasmid DNA produced in house

NorthX can produce plasmid DNA for your viral vector needs, simplifying your supply chain and allowing for quick turnaround times from plasmid to vector.


  • Working in small batch from early phase development process
  • Process design, optimization and scale up
  • Pre-clinical and clinical applications


  • Pre-clinical through to commercial mfg
  • GMP and non-GMP applications

Viral vectors produced by our biologics company:

NorthX Biologics is at the forefront of viral vector production, specializing in various vector types to suit diverse therapeutic applications. Each viral vector type offers unique characteristics that make them well-suited for specific gene therapy strategies.

Adeno-associated virus - AAV viral vector manufacturing

AAV is highly regarded for its low immunogenicity, non-pathogenic nature, and long-lasting gene expression, making it a preferred choice for sustained therapeutic effects.

Adenovirus - AV viral vector manufacturing

Adenoviral vectors are known for their high transduction efficiency in both dividing and non-dividing cells. Their ability to mediate rapid gene transfer makes them suitable for applications where immediate gene expression is essential.

Lenti-virus - LV viral vector manufacturing

LVs are particularly useful for delivering therapeutic genes into dividing and non-dividing cells. They are well-suited for long-term gene expression and are commonly employed in hematopoietic stem cell gene therapies.

Retrovirus - RV viral vector manufacturing

Retroviral vectors have a preference for actively dividing cells and have played a significant role in early gene therapy trials.

Work with a reliable partner for your viral vector production

NorthX Biologics, a leading biologics company, offers comprehensive production services for viral vectors, catering to both GMP and non-GMP applications, driving innovation and therapeutic breakthroughs in the field of advanced therapies.

Contact us

Learn more about viral vectors and vector manufacturing

What are viral vectors?

Viral vectors are specialized vehicles engineered from viral genomes to deliver therapeutic genetic material to target cells. These vehicles harness the natural ability of viruses to enter cells and transfer their genetic payload. The modification of viral genomes enables the removal of harmful components while retaining the virus's ability to transfect cells with the desired genetic material. Commonly used viral vectors include Adeno-associated virus (AAV), Adenovirus (AV), Lenti-virus (LV), and retro virus (RV).

These viral vectors serve as vehicles to deliver therapeutic genes into target cells. They have become the cornerstone of gene therapy, offering precise and efficient delivery of therapeutic genes to correct genetic abnormalities or introduce new functions to cells.

What are applications of viral vectors in gene therapy?

Gene therapies utilizing viral vectors have demonstrated tremendous potential in addressing genetic disorders, inherited diseases, and complex acquired conditions. Viral vectors efficiently deliver therapeutic genes into target cells, correcting faulty genetic sequences or introducing missing genes, thereby restoring normal cellular functions. These therapies hold promise for diseases that have been historically challenging to treat through traditional pharmaceutical approaches.

What is the manufacturing process of viral vectors?

The production of viral vectors is a multistep process that requires meticulous planning and optimization. It starts with the design and construction of the viral vector and the selection of the appropriate genetic payload, which will determine the therapeutic effect of the gene therapy.

1. Plasmid design and engineering:

In the early stages of viral vector development, the expression vector (plasmid) carrying the therapeutic gene is meticulously designed and engineered. The plasmid serves as the genetic backbone that carries the gene of interest and the necessary regulatory elements for gene expression.

2. Transfection systems for viral vector production:

Once the plasmid is ready, it needs to be introduced into host cells to enable viral vector replication. Several transfection systems are available, including transient transfection and stable producer cell lines. Transient transfection allows for short-term expression of the viral vector, whereas stable producer cell lines provide a continuous supply of vectors over extended periods.

What are different cell culture systems for viral vector production?

Viral vectors are produced using various cell culture systems, each offering distinct advantages depending on the vector type and desired outcomes. The choice of cell culture system significantly influences the yield and quality of the viral vectors.

Insect cells for viral vector production

Insect cells, such as those derived from the Spodoptera frugiperda (Sf9) cell line, are commonly used for the production of certain viral vectors like baculovirus-based vectors. Insect cell lines are well-suited for large-scale production due to their ability to grow in suspension culture, facilitating ease of scale-up in bioreactors.

Adherent systems for viral vector manufacturing

Adherent cell culture systems are employed for the production of a wide range of viral vectors. These systems are often used in early development stages and for small-scale production. Common adherent cells used include human embryonic kidney (HEK) cells and Vero cells.

Stable producer cell lines and cell factories

To achieve consistent and scalable viral vector production, stable producer cell lines are established. These cell lines are engineered to stably express the viral genes required for vector assembly. Cell factories, which are multilayer cell culture vessels, are used to expand the producer cells and increase productivity.

What are the cell expansion and cell banking upstream processes?

Viral vector production relies on the expansion of producer cells to achieve high cell densities, ensuring optimal vector yield and productivity. Furthermore, maintaining cell banks of stable producer cells is essential to ensure consistent and reproducible viral vector production over time.

  1. Cell Expansion: The process of cell expansion involves the controlled growth of producer cells in bioreactors or cell culture vessels. This expansion step is critical to achieving the required cell densities for optimal viral vector production.
  2. Cell Banking: Stable producer cell lines are preserved as cell banks, providing a reservoir of cells with the desired vector-producing characteristics. These cell banks are continuously monitored and validated to ensure the integrity and stability of the producer cells.

How do viral vector productors ensure quality during viral vector manufacturing?

Critical Quality Attributes (CQAs)

Maintaining the quality and consistency of viral vector products is of utmost importance. Identification and monitoring of critical quality attributes (CQAs) ensure that the final product meets the required specifications.

Purification process for viral vector products

The purification process is a critical step in viral vector manufacturing, as it removes impurities and concentrates the vector for further downstream processing. Purification typically involves a combination of chromatography, ultrafiltration, and other separation techniques.

Quality standards and regulatory compliance

Adherence to stringent quality standards and regulatory guidelines is imperative for the successful development and commercial manufacturing of viral vectors. Regulatory authorities, such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA), have established specific requirements for the production of gene therapies and viral vector products.

Learn more about various challenges of viral vector production quality
  1. Critical Quality Attributes (CQAs) of Viral Vectors: CQAs encompass various attributes, including vector titer, potency, purity, identity, and safety. Robust analytical methods are employed to assess these attributes throughout the manufacturing process and ensure compliance with quality standards.
  2. Challenges in Viral Vector Purification: Purifying viral vectors can be challenging due to the complexity of the vector particles and potential contamination from host cell components. Developing efficient purification processes is crucial to achieving high-quality vectors.
  3. Regulatory Approval for Viral Vector-Based Therapies: To gain market approval, manufacturers must demonstrate the safety, efficacy, and consistent quality of the viral vector products through preclinical and clinical studies. Meeting the expectations of regulatory authorities is essential for market entry and patient access.

How are raw materials selected for viral vectors?

Choosing the right raw materials is essential for viral vector production. High-quality components ensure reproducibility and consistency in the manufacturing process.

Raw materials for viral vector manufacturing include culture media, growth factors, supplements, and reagents needed for cell culture and vector production. The selection of raw materials is guided by their compatibility with the chosen cell culture system and their regulatory compliance.

The importance of plasmid design and engineering

Plasmids serve as the genetic backbone for viral vector constructs. Proper plasmid design and engineering are crucial to achieving efficient gene expression and vector replication.

Lentiviral vectors, unlike other vector types, require separate packaging and envelope plasmids to ensure safety and prevent recombination. This design allows for the production of replication-incompetent vectors. 

How are viral vectors used for advanced therapies and gene therapy development?

Viral vectors continue to be a key component in advancing gene therapies. Ongoing research and development are expected to improve vector design and enhance treatment outcomes through next-generation vectors for gene therapy. Researchers are exploring new vector designs and technologies, such as self-inactivating vectors and enhanced cell targeting, to improve the safety and efficacy of gene therapies.